I hope that is correct, and think there is some clues from Leo's communications in September through December of 2014 to believe that.
I'm saying that the designations that the FDA might grant and a partnership are far more important than the up-list. An up-list without the other items would be a short lived rally. Big news without the up-list can still create a sustained rally, and inevitably would lead to a definitive up-list. Of course, would prefer an up-list, tri-fecta, and partnership progression.
Market Data 
Markets 
AI
